| Filed On | Filing |
|---|---|
| 21 Oct 2026 |
Form 4: Wasserman Scott M., Director
Granted 310,000 Stock Option (Right to Buy) |
| 21 Oct 2026 |
Form 3: Wasserman Scott M., Director
No securities owned |
| 20 Oct 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure
WILMINGTON, Del., October 20, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial H... |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure
Disclaimer This presentation contains information that may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Inhibikase Therapeutics, Inc. (the “Company” or “w... |
| 26 Aug 2026 | 8-K: Changes in Registrant's Certifying Accountant |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 11 Aug 2026 | S-8 |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 31 Jul 2026 | SCHEDULE 13G/A |
| 31 Jul 2026 |
Form 4: Ra Capital MANAGEMENT, L.p., 10% owner and 3 others
Disposed of 18,030,000 shares (Other Transaction) · Acquired 18,030,000 Pre-Funded Warrant (Right to Buy) (Other Transaction) |
| 31 Jul 2026 |
Form 4: Berman Dennis N, Director
Received 21,854 shares by exercise or conversion ($27.5K) |
| 29 Jul 2026 | 8-K: Unregistered Sales of Equity Securities |
| 28 Jul 2026 | SCHEDULE 13G |
| 23 Jul 2026 | 8-K: Regulation FD Disclosure |
| 17 Jul 2026 |
Form 3: Ra Capital MANAGEMENT, L.p., 10% owner and 3 others
Holds 25,000,000 shares of Common Stock |
| 17 Jul 2026 | SCHEDULE 13G |
| 14 Jul 2026 | 8-K: Other Events |
Loading...
